JENNIFER WRUCK: Open Payments
NPI 1144998204 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$487 in 25 payments from 9 companies in 2025. Trend: 2023 $851 · 2024 $1,484 · 2025 $487
Food & beverage: $487
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 9 | $194 |
| ABBVIE INC. | 9 | $144 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Amgen Inc. | 1 | $20 |
| Fujifilm Healthcare Americas Corporation | 1 | $20 |
| Eton Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: MAVYRET, REZDIFFRA, XIFAXAN, OCALIVA, UPLIZNA, UTASWAKO AFP-L3, GALZIN, GATTEX.
Industry payments across TX — which companies pay providers there.
